4-(1-(4-Fluorophenyl)-2,5-dioxopyrrolidin-3-yl)piperazine-1-carbaldehyde

Catalog No. :
ACSVFT748
CAS No. :
330865-91-3
Molecular Formula :
C15H16FN3O3
Molecular Weight :
305.31

IUPAC Name:4-(1-(4-fluorophenyl)-2,5-dioxopyrrolidin-3-yl)piperazine-1-carbaldehyde

4-(1-(4-Fluorophenyl)-2,5-dioxopyrrolidin-3-yl)piperazine-1-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(1-(4-Fluorophenyl)-2,5-dioxopyrrolidin-3-yl)piperazine-1-carbaldehyde
IUPAC Name4-(1-(4-fluorophenyl)-2,5-dioxopyrrolidin-3-yl)piperazine-1-carbaldehyde
Molecular FormulaC15H16FN3O3
Molecular Weight305.31
SMILESO=CN1CCN(C(C2)C(N(C3=CC=C(F)C=C3)C2=O)=O)CC1
InChI KeyWMVUAJDVQZANHV-UHFFFAOYSA-N
Synonym4-[1-(4-FLUOROPHENYL)-2,5-DIOXO-3-PYRROLIDINYL]-1-PIPERAZINECARBALDEHYDE;1-Piperazinecarboxaldehyde, 4-[1-(4-fluorophenyl)-2,5-dioxo-3-pyrrolidinyl]-
CAS No.330865-91-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACSVFT748 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACSJBL806 route compound structure diagram
    ACSJBL8067755-92-2 In Stock
  4. Then
  5. ACSVFT748 route product structure diagram
    ACSVFT748330865-91-3
Inquiry

2. ACSVFT748 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEDMW612 route compound structure diagram
    ACEDMW6126108-23-2 In Stock
  4. Then
  5. ACSVFT748 route product structure diagram
    ACSVFT748330865-91-3
Inquiry

Comments (0)